352 filings
8-K
BXRX
Baudax Bio, Inc.
28 Feb 24
Bankruptcy or Receivership
6:15am
25-NSE
The Nasdaq Stock Market LLC
15 Feb 24
Exchange delisting
8:53am
SC 13G/A
Black Horse Capital LP
14 Feb 24
Baudax Bio / BLACK HORSE CAPITAL ownership change
10:25am
SC 13G/A
BXRX
Baudax Bio, Inc.
6 Feb 24
Baudax Bio / INTRACOASTAL CAPITAL ownership change
11:12am
8-K
BXRX
Baudax Bio, Inc.
12 Dec 23
Other Events
9:52pm
424B3
BXRX
Baudax Bio, Inc.
22 Nov 23
Prospectus supplement
4:58pm
10-Q
2023 Q3
BXRX
Baudax Bio, Inc.
Quarterly report
20 Nov 23
5:28pm
NT 10-Q
BXRX
Baudax Bio, Inc.
15 Nov 23
Notice of late quarterly filing
5:25pm
8-K
BXRX
Baudax Bio, Inc.
15 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
BXRX
Baudax Bio, Inc.
25 Oct 23
Changes in Registrant's Certifying Accountant
7:57am
8-K
BXRX
Baudax Bio, Inc.
13 Oct 23
Submission of Matters to a Vote of Security Holders
7:00am
3
Natalie McAndrew
11 Oct 23
Baudax Bio / Natalie McAndrew ownership change
4:47pm
DEFA14A
BXRX
Baudax Bio, Inc.
10 Oct 23
Additional proxy soliciting materials
7:00am
8-K
BXRX
Baudax Bio, Inc.
6 Oct 23
Departure of Directors or Certain Officers
8:00am
8-K
BXRX
Baudax Bio, Inc.
29 Sep 23
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
7:01am
EFFECT
BXRX
Baudax Bio, Inc.
26 Sep 23
Notice of effectiveness
12:15am
EFFECT
BXRX
Baudax Bio, Inc.
26 Sep 23
Notice of effectiveness
12:15am
S-1/A
BXRX
Baudax Bio, Inc.
IPO registration (amended)
21 Sep 23
5:30pm
S-3/A
BXRX
Baudax Bio, Inc.
Shelf registration (amended)
21 Sep 23
4:48pm
CORRESP
BXRX
Baudax Bio, Inc.
21 Sep 23
Correspondence with SEC
12:00am